Literature DB >> 7907612

Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: comparison of cryostat and paraffin wax sections and effect of fixation.

K Y Chiu1, S L Loke, F C Ho.   

Abstract

AIMS: To investigate the effects of fixation on the immunohistochemical demonstration of c-erbB-2 oncoprotein using paraffin wax and cryostat sections; to compare c-erbB-2 expression in non-neoplastic and neoplastic gastric tissues.
METHODS: Adjacent blocks of tumour and non-neoplastic tissue from four gastrectomy specimens were put into a panel of 10 fixatives including acetone, B5, Bouin's fluid, Carnoy's fluid, buffered formalin, formol dichromate, zinc formalin, 4% paraformaldehyde, periodate-lysine-paraformaldehyde (PLP) and periodate-lysine-paraformaldehyde-dichromate (PLPD) before embedding in paraffin wax for sectioning. Similar tissue blocks were snap frozen and cryostat sections were postfixed in these fixatives, either alone or in combination, before immunostaining.
RESULTS: In paraffin wax embedded sections the best fixative was PLP, and in frozen tissues the best results were obtained after fixation of cryostat sections in buffered formalin followed by cold methanol and acetone. Applying these fixatives to samples from a further 16 gastrectomy specimens, strong membrane staining of c-erbB-2 protein was found in the tumour in eight of 16 cases (50%) using paraffin wax sections, and staining was stronger in the better differentiated carcinomas. For frozen tissues, positive membrane staining was found in all gastric adenocarcinomas, but differential staining intensity associated with tumour differentiation could not be detected.
CONCLUSIONS: These results indicate that fixation and paraffin wax embedding affect the results of immunohistochemical demonstration of c-erbB-2 in gastric cancer. The choice of fixative is critical in the demonstration and evaluation of c-erbB-2 protein expression by immunohistochemistry in gastric carcinomas. Staining results also vary depending on whether frozen or paraffin wax embedded tissues are studied.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7907612      PMCID: PMC501823          DOI: 10.1136/jcp.47.2.117

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  12 in total

1.  Gene amplification in gastric and esophageal adenocarcinomas.

Authors:  J Houldsworth; C Cordon-Cardo; M Ladanyi; D P Kelsen; R S Chaganti
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

2.  Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer.

Authors:  Y Yonemura; I Ninomiya; A Yamaguchi; S Fushida; H Kimura; S Ohoyama; I Miyazaki; Y Endou; M Tanaka; T Sasaki
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

3.  C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia.

Authors:  P L Porter; R Garcia; R Moe; D J Corwin; A M Gown
Journal:  Cancer       Date:  1991-07-15       Impact factor: 6.860

4.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

Authors:  J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason
Journal:  J Histochem Cytochem       Date:  1984-02       Impact factor: 2.479

5.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue.

Authors:  J Yokota; T Yamamoto; N Miyajima; K Toyoshima; N Nomura; H Sakamoto; T Yoshida; M Terada; T Sugimura
Journal:  Oncogene       Date:  1988-03       Impact factor: 9.867

8.  A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.

Authors:  K Semba; N Kamata; K Toyoshima; T Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

9.  Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification.

Authors:  T Kameda; W Yasui; K Yoshida; T Tsujino; H Nakayama; M Ito; H Ito; E Tahara
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

10.  Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

Authors:  J Yokota; T Yamamoto; K Toyoshima; M Terada; T Sugimura; H Battifora; M J Cline
Journal:  Lancet       Date:  1986-04-05       Impact factor: 79.321

View more
  2 in total

1.  c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus.

Authors:  R H Hardwick; N A Shepherd; M Moorghen; P V Newcomb; D Alderson
Journal:  J Clin Pathol       Date:  1995-02       Impact factor: 3.411

2.  Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.

Authors:  P M Schneider; H W Praeuer; O Stoeltzing; J Boehm; J Manning; R Metzger; U Fink; S Wegerer; A H Hoelscher; J A Roth
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.